Health
Eli Lilly says retatrutide trial showed greater weight loss than Ozempic
Business Insider reports Eli Lilly's head-to-head trial found greater weight loss on retatrutide than on Ozempic, with results not yet peer-reviewed.
The short version
- Eli Lilly announced head-to-head trial results comparing its investigational drug retatrutide with Ozempic in type 2 diabetes patients.[Business Insider]
- Retatrutide users lost an average of 44 to 47 pounds over about 1.5 years, versus 21 pounds on the highest Ozempic dose, with larger A1C reductions.[Business Insider]
- The results have not been peer-reviewed or published, and Eli Lilly expects to submit retatrutide to the FDA in early 2027.[Business Insider]
Key facts
- Eli Lilly announced results from its first clinical trial comparing Ozempic against its investigational drug retatrutide.[Business Insider]
- Over about a year and a half, type 2 diabetes patients on the highest Ozempic dose lost an average of 21 pounds.[Business Insider]
- Retatrutide patients lost an average of 44 pounds at 9 mg and 47 pounds at 12 mg over the same period.[Business Insider]
- Retatrutide patients saw average A1C reductions of 2.2%, compared with 1.8% for Ozempic.[Business Insider]
- Eli Lilly expects to submit retatrutide to the US Food and Drug Administration for approval in early 2027.[Business Insider]
- The clinical trial results have not yet been peer-reviewed or published in a medical journal.[Business Insider]
What remains uncertain
- The trial results are company-released and have not been peer-reviewed or published in a medical journal.[Business Insider]
- Retatrutide is not yet approved, and whether regulators will approve it is unknown; FDA submission is only expected in early 2027.[Business Insider]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.
- Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight lossBusiness Insider metered